News

The company enrolled 22 patients with advanced, previously treated solid tumors in the study before closing enrollment in July 2007. The results concern 19 patients evaluated for safety

INGN 225 is an immunotherapy using a patient's own cells to stimulate an anti-tumor immune response to fight cancer. The immunotherapeutic targets a molecular abnormality found in over

Under the terms of the agreement, the costs of the collaboration projects will be borne 60% by Aradigm and 40% by CyDex, with third-party licensing and sales revenues

The company reported that exposure to its drug and metformin did not change to a clinically relevant extent when they were co-administered, compared with each therapy alone. “This

This license includes access to Idea's Transfersome technology platform that delivers drugs locally to targeted areas. In May 2007, Idea AG submitted a marketing authorization application in Europe

The randomized Phase II trial for the Stimuvax MUC-1 vaccine was conducted in non-small cell lung cancer (NSCLC) patients. Merck says the results suggest that Stimuvax combined with

Changchun Xinan (CCXA) is a privately owned business primarily serving the rural healthcare market with more than 100 plant-based pharmaceutical products in its portfolio. American Oriental Bioengineering (AOBO)

The decision was based in part on the agency’s guidance that a primary endpoint analysis of less than the initially-projected 320 eligible patients could be acceptable for new

Through the FDA’s special protocol assessment (SPA) process, Kosan and the FDA have reached agreement on overall protocol design, primary efficacy endpoints and data analysis as well as